US-based biotechnology company Alltrna is developing transfer RNA (tRNA)-based therapies that aim to offer a broad solution for thousands of rare genetic diseases by targeting common mutations rather ...

All living organisms encode the amino acid sequences of proteins as nucleotide sequences (genetic information) in their genomic DNA. The genetic information is transcribed and subsequently translated ...

HC Bioscience is shutting down after conducting preclinical models for a transfer RNA (tRNA) asset designed to treat hemophilia A. The Cambridge, Massachusetts-based biotech is closing “following ...

Between 10 to 15% of all genetic diseases have the same underlying cause: a nonsense mutation. 1 This type of mutation results from a stop codon in the middle of a gene sequence, which terminates ...

Raghu R. Chivukula, MD, PhD, a physician-investigator in the Departments of Medicine & Surgery and the Center for Genomic Medicine at Massachusetts General Hospital and Harvard Medical School, is the ...

Alltrna is the latest in a growing number of startups with plans to develop therapies based on transfer RNA (tRNA), a family of RNA molecules that play a vital role in building proteins. The Cambridge ...

The study's main contributors include (L-R) graduate student Joshua Shaffer, professor Upasna Sharma, and postdoc Alka Gupta. (Photo by Carolyn Lagattuta) The pioneering research of UC Santa Cruz’s ...

To build proteins, cells rely on a molecule called transfer RNA, or tRNA. tRNAs act like protein-building couriers, where they read the genetic instructions from messenger RNA, mRNA, and deliver the ...

A team of researchers led by University of California, Riverside biomedical scientists has identified a small, previously overlooked small RNA molecule that plays a major role in controlling the ...